99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Breast Cancer
Interventions
RADIATION

99mTc-3PRGD2

"Diagnostic group:For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.~Efficacy evaluation group:patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment),whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers."

Trial Locations (1)

350005

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER

NCT02742168 - 99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients | Biotech Hunter | Biotech Hunter